Barbara Faganel Kotnik
Klinični oddelek za otroško hematologijo in onkologijo, Pediatrična klinika, Univerzitetni klinični center Ljubljana, Ljubljana, Slovenija

Alenka Trampuš Bakija
Klinični inštitut za specialno laboratorijsko diagnostiko, Pediatrična klinika, Univerzitetni klinični center Ljubljana, Ljubljana, Slovenija

Tadej Avčin
Klinični oddelek za otroško alergologijo, revmatologijo in klinično imunologijo, Pediatrična klinika, Univerzitetni klinični center Ljubljana, Ljubljana in Univerza v Ljubljani, Medicinska fakulteta, Ljubljana, Slovenija

Lidija Kitanovski
Klinični oddelek za otroško hematologijo in onkologijo, Pediatrična klinika, Univerzitetni klinični center Ljubljana, Ljubljana, Slovenija

Abstract

Acute SARS-CoV-2 infection may be accompanied by a hypercoagulable state with thromboembolic events, SAR-S-CoV-2-associated coagulopathy, and disseminated intra-vascular coagulation due to activation of the coagulation pathway. Two to six weeks after infection, children may develop a multisystem inflammatory response when the risk of thromboembolic disease is again increased due to widespread vascular endothelial damage and numerous coagulation and inflammatory factors. We present national recommendations for pharmacological anticoagulant thromboprophylaxis in children and adolescents with SARS-CoV-2 infection as outpatients, in hospital or in the intensive care unit. Treatment of children and adolescents with congenital bleeding disorders, known congenital thrombophilia and inserted central venous catheter is specified separately.

Key words: SARS-CoV-2, anticoagulant prophylaxis, children